CRBU

Caribou Biosciences, Inc.

1.56 USD

Last updated Sep 4, 20:05 UTC

Yesterday HIGH

$1.61

Yesterday LOW

$1.53

52w HIGH

$3.53

52w LOW

$1.38

EPS

-0.24

PE

-6.50

Next Earnings

Nov 11, 2026

Overview News Government Trades Fundamentals

Caribou Biosciences, Inc. stock is down -3.11% since 30 days ago. The next earnings date is Nov 11, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 5 September’s closed higher than August. 100% of analysts rate it a buy.

Benzinga Newsdesk

Fri Aug 14, 2026

B of A Securities Maintains Buy on Caribou Biosciences, Lowers Price Target to $5

B of A Securities analyst Alec Stranahan maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and lowers the price target from $6 to $5.
Benzinga Newsdesk

Thu Aug 13, 2026

Caribou Biosciences Q2 EPS $(0.24) Beats $(0.32) Estimate, Sales $1.499M Miss $2.279M Estimate

Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.32) by 25 percent. This is a 31.43 percent increase over losses of $(0.35) per share from
Benzinga Newsdesk

Thu Jun 11, 2026

Caribou Biosciences Reports Longer Follow Up Data For Ongoing CaMMouflage Phase 1 Trial Of CB-011, Off-The-Shelf BCMA-Targeted CAR-T Cell Therapy, Being Evaluated For r/r MM

-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months ---- Case study of a patient who
Benzinga Newsdesk

Tue May 12, 2026

Caribou Biosciences To Present Phase 1 CAR-T Therapy Data For vispa-cel And CB-011 At EHA 2026 Annual Meeting

Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for oral presentations at the 2026 European Hematology
Benzinga Newsdesk

Mon May 11, 2026

HC Wainwright & Co. Maintains Buy on Caribou Biosciences, Raises Price Target to $11

HC Wainwright & Co. analyst Robert Burns maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and raises the price target from $9 to $11.
Benzinga Newsdesk

Thu May 7, 2026

Caribou Biosciences Q1 EPS $(0.26) Beats $(0.31) Estimate, Sales $2.397M Beat $2.241M Estimate

Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 39.53 percent increase over losses of $(0.43) per share
Benzinga Newsdesk

Tue Apr 7, 2026

HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Caribou Biosciences (NASDAQ:CRBU) with a Buy and maintains $9 price target.